CKD: Folate (2018)
Author and Year:
Zoungas S et al. 2006
Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial.
Zoungas S, McGrath B, Branley P, Kerr P, Muske C, Wolfe R, Atkins R, Nicholls K, Fraenkel M, Hutchison B, Walker R,McNeil J
Journal of the American College of Cardiology
Year of publication:
Randomized Controlled Trial
Risk of Bias Assessment Rating:
Age over 18 years with CRF of any cause a serum creatinine of 0.4 mmol/l or greater either awaiting dialysis or already treated with continuous ambulatory peritoneal dialysis intermittent peritoneal dialysis or hemodialysis
Does not meet inclusion criteria.
To determine whether high-dose folic acid supplementation would slow the progression of carotid artery intima-media thickness (IMT) and reduce the incidence of cardiovascular events (a composite end point of myocardial infarction, stroke, and death from cardiovascular cause) in this population. The differences between the treatment groups in all fatal and nonfatal cardiovascular events and indices of arterial function (pulse wave velocity [PWV], systemic arterial compliance [SAC], and augmentation index [AIx]) were also studied.
Source(s) of Funding:
Please specify names of funders:
supported by grants-in-aid from the National Health and Medical Research Council of Australia and National Kidney Foundation of New Zealand.